2024-07-16 01:12:48 ET
Summary
- The good things to note about WXIBF is that the outlook for biotech funding is favorable, considering expectations of a rate cut this year, and the stock's potential buyback yield is appealing.
- The bad thing about WuXi Biologics is that the company's US market prospects appear to be unfavorable, taking into account geopolitical risk factors.
- A Hold rating for WuXi Biologics is retained after analyzing the stock's positive and negative factors.
Elevator Pitch
I assign a Hold investment rating to WuXi Biologics (Cayman) Inc. ( OTCPK:WXIBF ) ( OTCPK:WXXWY ) [2269:HK] stock. My previous April 24, 2024 write-up assessed WuXi Biologics' financial outlook and valuation metrics. The company describes itself as "a leading global Contract Research, Development and Manufacturing Organization (CRDMO)" on its corporate website ....
Read the full article on Seeking Alpha
For further details see:
The Good And The Bad For WuXi Biologics